Current and Emerging Role of Radiogenomics

Rate:
N/A
added:
4 years ago
views:
484
specialty:
Urology

Case description

John Feller, MD, Founding Partner and Medical Director at Desert Medical Imaging, gives an overview of radiogenomics’ current and possible future role in prostate cancer care. He notes the recent promising results of multiparametric MRI (mpMRI) from trials, which have shown that using mpMRI before transrectal ultrasound-guided (TRUS) biopsy can decrease the number of unnecessary biopsies, limit detection of insignificant cancer, and improve detection of significant cancer. These have influenced the updated 2019 National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer. Dr. Feller further discusses other biomarkers for risk stratification and promising research on radiogenomics in the setting of focal therapy.

tags: prostate cancer multiparametric MRI mpMRI transrectal ultrasound-guided biopsy TRUS PSA


This user also sharing

Recommended

show more